Alkem Laboratories Limited saw its shares drop over 3% following the announcement of its Q3 FY25 results. As of 2:05 PM, the shares were trading 2.30% lower at Rs 5,134.70.
The pharmaceutical company reported a 1.5% year-on-year (YoY) increase in revenue from operations, reaching ₹3,374.28 crore, while total income rose by 1% to ₹3,467.27 crore.
Profitability showed a strong upward trend, with profit before tax (PBT) surging 12% YoY to ₹731.07 crore and net profit (PAT) climbing 4% to ₹640.79 crore. The company’s operational efficiencies contributed to this growth, reflected in an EBITDA of ₹760 crore, surpassing estimates and last year’s ₹708 crore. Additionally, the EBITDA margin expanded to 22.51%, beating both last year’s 21.29% and market expectations of 20.5%.
Alkem Laboratories also announced an interim dividend of ₹37 per equity share on a face value of ₹2 per share for FY25. The record date for eligibility is February 14, 2025, with dividend payments commencing on February 28, 2025.
Alkem Laboratories’ shares opened at ₹5,299.40, reaching a high of ₹5,318.00 and a low of ₹5,036.00. The stock remains volatile, with a 52-week high of ₹6,439.90 and a low of ₹4,407.05.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
